Genomics

Colorectal Cancer Market Driven By Epigenomics AG, Novigenix SA, Clinical Genomics Technologies – KSU


The Colorectal Cancer market is anticipated to reach US$ 22,953.8 Mn in 2027 from US$ 16,339.9 Mn in 2018. The market is anticipated to grow with a CAGR of 4.0% from 2019-2027.

The report provides trends prevailing in the global colorectal cancer market and the factors driving the market along with those that act as hindrances. The market for colorectal cancer is expected to grow, owing to factors such as increasing prevalence of colorectal cancer, new product launches and benefits offered by generic drugs. Moreover, growing pharmaceutical industry in emerging economies is likely to have a positive impact on the growth of the market in the coming years.

Download PDF Sample Report Here: https://www.theinsightpartners.com/sample/TIPRE00006881/

Competitive Landscape Colorectal Cancer Market: Epigenomics AG, Novigenix SA, Clinical Genomics Technologies Pty Ltd., EDP Biotech Corporation, Volitionrx Limited, Abbott Laboratories, Amgen Inc., F. Hoffmann-La Roche AG, Bruker Corporation, Quest Diagnostics Incorporated, Natera, Inc., and Guardant Health.

The global colorectal cancer market, based on the modality, is segmented into diagnosis type, therapy type, and imaging type. In 2018, the diagnosis type segment held the largest market share of the colorectal cancer market. This segment is also projected to dominate the market in 2027 as it emphasizes the need for early recognition of neoplasms, or in the asymptomatic or pre-cancerous stage.

The market for colorectal cancer is expected to grow, owing to factors such as increasing prevalence of colorectal cancer, new product launches and benefits offered by generic drugs. Moreover, growing pharmaceutical industry in emerging economies is likely to have a positive impact on the growth of the market in the coming years.

Furthermore, the companies are also focused on the development of new diagnostic tests that will help in the accurate detection of colorectal cancer. For instance, in December 2016, Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer, introduced Colvera, a blood-based diagnostic test for colorectal cancer recurrence monitoring.

Our Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology

Reasons to Buy:

  1. The nature of Colorectal Cancer business opportunities has grown in complexity with the industry evolving at a greater pace, making it increasingly difficult going without adequate information on markets and companies.
  2. Gain a complete understanding of Global Colorectal Cancer industry through the comprehensive analysis
  3. Evaluate the pros and cons of investing/operating in country level Colorectal Cancer markets through reliable forecast model results
  4. Identify potential investment/contract/expansion opportunities
  5. Drive your strategies in the right direction by understanding the impact of latest trends, market forecasts on your Colorectal Cancer business
  6. Beat your competition through information on their operations, strategies and new projects
  7. Recent insights on the Colorectal Cancer market will help users operating in the market to initiate transformational growth

Interested in Purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00006881/

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Call: +1-646-491-9876

Email: sales@theinsightpartners.com



Source link

Most Popular

To Top